Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Cash from Financing Activities (2019 - 2023)

Alx Oncology Holdings' Cash from Financing Activities history spans 5 years, with the latest figure at $59.2 million for Q4 2023.

  • For Q4 2023, Cash from Financing Activities rose 523.19% year-over-year to $59.2 million; the TTM value through Dec 2023 reached $59.3 million, up 501.33%, while the annual FY2025 figure was $362000.0, 98.83% down from the prior year.
  • Cash from Financing Activities for Q4 2023 was $59.2 million at Alx Oncology Holdings, up from -$111000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $188.4 million in Q4 2020 and bottomed at -$769000.0 in Q2 2020.
  • The 5-year median for Cash from Financing Activities is $524000.0 (2021), against an average of $31.8 million.
  • The largest annual shift saw Cash from Financing Activities surged 3078.02% in 2020 before it plummeted 233.75% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $5.9 million in 2019, then soared by 3078.02% to $188.4 million in 2020, then plummeted by 99.72% to $524000.0 in 2021, then soared by 1711.83% to $9.5 million in 2022, then surged by 523.19% to $59.2 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Cash from Financing Activities are $59.2 million (Q4 2023), -$111000.0 (Q3 2023), and $343000.0 (Q2 2023).